Market Currents
Supernus (SUPN) soars 40% after it receives tentative FDA approval for its Trokendi XR treatment...
-
Tuesday, June 26, 2012, 8:28 AM ETSupernus (SUPN) soars 40% after it receives tentative FDA approval for its Trokendi XR treatment for epilepsy. Final authorization is conditional on Supernus resolving a marketing exclusivity issue regarding a specific pediatric population. The FDA also denies a Citizen's Petition filed in 2011 by Upsher Smith Labs related to its NDA on Trokendi XR.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
